Previous 10 | Next 10 |
2023-03-28 10:00:38 ET Gainers: Biomea Fusion ( BMEA ) +56% . Oscar Health ( OSCR ) +54% . Viking Therapeutics ( VKTX ) +51% . Intra-Cellular Therapies ( ITCI ) +20% . Guardion Health Sciences ( GHSI ) +17% . Losers...
2023-03-28 08:43:59 ET Intra-Cellular Therapies ( NASDAQ: ITCI ) added ~14% on Tuesday in the pre-market trading after announcing that its depression candidate lumateperone reached the key goals in a trial for patients with depressive episodes. Study 403 was a randomized...
Lumateperone 42mg was statistically significant on the primary endpoint of symptom reduction on the Montgomery Asberg Depression Rating Scale (MADRS) for each patient population including: -combined major depressive disorder (MDD) with mixed features and bipolar depression with mixed fe...
2023-03-05 21:14:52 ET Summary Intra-Cellular Therapies develops small-molecule drugs targeting the central nervous system for neuropsychiatric and neurological disorders. Caplyta is their lead drug, approved by the FDA for schizophrenia and bipolar depression. Caplyta's exception...
Intra-Cellular Therapies, Inc. (ITCI) Q4 2022 Earnings Conference Call March 01, 2023 08:30 A.M. ET Company Participants Juan Sanchez - VP, Corporate Communications & IR Sharon Mates - Founder, Chairman, and CEO Mark Neumann - EVP & Chief Commercial Officer ...
Intra-Cellular Therapies press release ( NASDAQ: ITCI ): Q4 GAAP EPS of -$0.45 beats by $0.15 . Revenue of $87.87M (+242.3% Y/Y) beats by $0.9M . CEO comment: "We expect 2023 to be another year of significant growth for CAPLYTA and the company.” CAPLYTA 2023...
Full year 2022 total revenues of $250.3 million, compared to $83.8 million in 2021 CAPLYTA fourth quarter 2022 net product sales grew to $87.4 million, a 243% increase over the same period in 2021 and a 22% sequential increase over the third quarter 2022 Full year 2022 CAPL...
Intra-Cellular Therapies ( NASDAQ: ITCI ) is scheduled to announce Q4 earnings results on Wednesday, March 1st, before market open. The consensus EPS Estimate is -$0.59 (+43.8% Y/Y) and the consensus Revenue Estimate is $86.97M (+238.8% Y/Y). Over the last 1 year, ITCI has b...
Major earning expected before the bell on Wednesday include: Amarin ( AMRN ) Lowe's Companies ( LOW ) NIO ( NIO ) Royal Bank of Canada ( RY ) Workhorse Group ( WKHS ) For further details see: Notable earnings before Wednesday's open
NEW YORK, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced it will host a conference call and live webcast ...
News, Short Squeeze, Breakout and More Instantly...
Intra-Cellular Therapies Inc. Company Name:
ITCI Stock Symbol:
NASDAQ Market:
Intra-Cellular Therapies Inc. Website:
2024-06-20 15:00:05 ET Graig Suvannavejh from Mizuho Securities issued a price target of $100.00 for ITCI on 2024-06-20 12:10:00. The adjusted price target was set to $100.00. At the time of the announcement, ITCI was trading at $76.06. The overall price target consensus...
In Study 502, lumateperone 42 mg achieved statistically significant and clinically meaningful results in both the primary and the key secondary endpoints Lumateperone 42 mg met the primary endpoint of change from baseline at Week 6 on the Montgomery- Åsberg Depression Rating Sc...
NEW YORK, June 10, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Office...